The following article is a part of conference coverage from the American College of Allergy, Asthma & Immunology 2020 Annual Scientific Meeting, being held virtually from November 13-15, 2020. The team at Pulmonology Advisor will be reporting on the latest news and research conducted by leading experts in the field. Check back for more from the ACAAI 2020 Annual Scientific Meeting.
The 3-month Asthma Impairment and Risk Questionnaire (AIRQ™) demonstrated a similar ability to differentiate asthma control as the 12-month AIRQ, according to research presented at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting, held virtually from November 13 to 15.
The AIRQ is a 10-item, yes/no control tool that has been cross-sectionally validated in 442 patients aged 12 years and older who are part of a larger longitudinal study. Compared with the Asthma Control Test (ACT™), cut points of fewer than 2 yes responses demonstrate a sensitivity of 0.90 to identify well controlled asthma and 5 or more yes responses demonstrate a specificity of 0.96 to identify very poorly controlled asthma.
Researchers of the current study evaluated a 3-month AIRQ that used the same impairment and risk items but with 3-month exacerbation questions to assess whether repetitive use over shorter time periods, rather than yearly, was feasible.
AIRQ at baseline and 3-month AIRQ at 3 and 6 months were assessed in 1106 patients against ACT exacerbations (prior year chart-documented and monthly self-reported over months 1-3 and 4-6). Construct validity was analyzed by proportion of well, not well, and very poorly controlled asthma in patients having at least 2 exacerbations. Approximately 70.1% of the patients were women, and the mean age was 43 years.
Baseline AIRQ and 3-month AIRQ at 3 and 6 months showed 78.2% (baseline prior year), 84.1% (months 1-3), and 86.5% (months 4-6) of the patients with well controlled asthma as well controlled according to the ACT exacerbations standard. Furthermore, 56.7% (baseline prior year), 73.5% (months 1-3), and 70.6% (months 4-6) of patients with very poorly controlled asthma scores were in the comparable ACT exacerbations group.
As each control category worsened, the proportion of patients having at least 2 exacerbations increased (baseline prior year, 5.4%, 24.0%, 40.9%; month 3 prior 3 months: 2.8%, 12.1%, and 25.3%; month 6 prior 3 months: 2.2%, 13.3%, 28.2%; P <.001).
The study authors concluded that the 3-month AIRQ had a similar ability to determine levels of asthma control as the 12-month version, providing a tool for repeated assessments.
Chipps B, Murphy K, Wise R, et al. Evaluating performance of the Asthma Impairment and Risk Questionnaire (AIRQ™) at 3-month intervals. Presented at: the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (Virtual Experience); November 13-15, 2020. Abstract P223.
Visit Pulmonology Advisor’s conference section for complete coverage of ACAAI 2020 Annual Scientific Meeting.